In quest to eliminate tropical diseases, Merck KGaA will submit anti-worming drug for approval in young children
As Merck KGaA makes moves to treat the neglected tropical disease schistosomiasis, it has announced that its treatment arpraziquantel has yielded positive Phase III trial results in children between the ages of 3 months and 6 years old, and the company will now seek regulatory approval.
A pediatric version of the standard drug praziquantel, arpraziquantel is an anti-worm medication that prevents newly hatched, parasitic worms from growing or multiplying inside a patient. The trial could offer a cure for millions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.